{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T08:23:02Z","timestamp":1775895782421,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s10147-025-02837-8","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T01:43:13Z","timestamp":1753148593000},"page":"1963-1971","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world treatment outcomes before and after chemoimmunotherapy approval in EGFR-mutant NSCLC after EGFR-TKI failure: a Japanese cohort study"],"prefix":"10.1007","volume":"30","author":[{"given":"Kenji","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6945-281X","authenticated-orcid":false,"given":"Tadaaki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Hibino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahito","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Goto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Ogusu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taishi","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayo","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Masubuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae","family":"Hata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoki","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoichi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Date","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Chihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"2837_CR1","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"key":"2837_CR2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P et al (2015) Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373:123\u2013135. https:\/\/doi.org\/10.1056\/NEJMoa1504627","journal-title":"N Engl J Med"},{"key":"2837_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41423-020-00577-5","volume":"18","author":"F Zhou","year":"2021","unstructured":"Zhou F, Qiao M, Zhou C (2021) The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cell Mol Immunol 18:279\u2013293. https:\/\/doi.org\/10.1038\/s41423-020-00577-5","journal-title":"Cell Mol Immunol"},{"key":"2837_CR4","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.21037\/tlcr-23-581","volume":"12","author":"K Morimoto","year":"2023","unstructured":"Morimoto K, Yamada T, Takayama K (2023) The landscape of immune therapy in vulnerable patients with advanced non-small cell lung cancer: a narrative review. Transl Lung Cancer Res 12:2310\u20132321. https:\/\/doi.org\/10.21037\/tlcr-23-581","journal-title":"Transl Lung Cancer Res"},{"key":"2837_CR5","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres J, Drilon A, Lusque A et al (2019) Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the immunotarget registry. Ann Oncol 30:1321\u20131328. https:\/\/doi.org\/10.1093\/annonc\/mdz167","journal-title":"Ann Oncol"},{"key":"2837_CR6","unstructured":"Japan Pharmaceuticals, Medical Devices Agency (PMDA). https:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/approved-information\/drugs\/0003.html. Accessed 10 Jan 2025"},{"key":"2837_CR7","doi-asserted-by":"publisher","first-page":"108447","DOI":"10.1016\/j.lungcan.2025.108447","volume":"201","author":"K Morimoto","year":"2025","unstructured":"Morimoto K, Yamada T, Furuya N et al (2025) Exploration of clinical biomarkers for guiding treatment selection between chemotherapy and combination therapy with atezolizumab, bevacizumab, carboplatin, and paclitaxel in EGFR-mutant NSCLC patients after EGFR-TKI therapy: the SPIRAL-STEP study. Lung Cancer 201:108447. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108447","journal-title":"Lung Cancer"},{"key":"2837_CR8","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1200\/JCO.23.02747","volume":"42","author":"JC Yang","year":"2024","unstructured":"Yang JC, Lee DH, Lee JS et al (2024) Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer. J Clin Oncol 42:4029\u20134039. https:\/\/doi.org\/10.1200\/JCO.23.02747","journal-title":"J Clin Oncol"},{"key":"2837_CR9","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1200\/JCO.23.01891","volume":"42","author":"S Park","year":"2024","unstructured":"Park S, Kim TM, Han JY et al (2024) Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04). J Clin Oncol 42:1241\u20131251. https:\/\/doi.org\/10.1200\/JCO.23.01891","journal-title":"J Clin Oncol"},{"key":"2837_CR10","doi-asserted-by":"publisher","first-page":"100388","DOI":"10.1016\/j.jtocrr.2022.100388","volume":"3","author":"K Morimoto","year":"2022","unstructured":"Morimoto K, Sawada R, Yamada T et al (2022) A real-world analysis of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with EGFR-mutant NSCLC. JTO Clin Res Rep 3:100388. https:\/\/doi.org\/10.1016\/j.jtocrr.2022.100388","journal-title":"JTO Clin Res Rep"},{"key":"2837_CR11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00262-020-02662-0","volume":"70","author":"E Ichihara","year":"2021","unstructured":"Ichihara E, Harada D, Inoue K et al (2021) Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors. Cancer Immunol Immunother 70:101\u2013106. https:\/\/doi.org\/10.1007\/s00262-020-02662-0","journal-title":"Cancer Immunol Immunother"},{"key":"2837_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transpl"},{"key":"2837_CR13","doi-asserted-by":"publisher","first-page":"e721","DOI":"10.1016\/j.cllc.2018.05.014","volume":"19","author":"H Kawachi","year":"2018","unstructured":"Kawachi H, Fujimoto D, Morimoto T et al (2018) Clinical characteristics and prognosis of patients with advanced non-small-cell lung cancer who are ineligible for clinical trials. Clin Lung Cancer 19:e721\u2013e734. https:\/\/doi.org\/10.1016\/j.cllc.2018.05.014","journal-title":"Clin Lung Cancer"},{"key":"2837_CR14","doi-asserted-by":"publisher","first-page":"102602","DOI":"10.1016\/j.ctrv.2023.102602","volume":"119","author":"I Attili","year":"2023","unstructured":"Attili I, Passaro A, Corvaja C et al (2023) Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: a systematic review. Cancer Treat Rev 119:102602. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102602","journal-title":"Cancer Treat Rev"},{"key":"2837_CR15","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018\u20132028. https:\/\/doi.org\/10.1056\/NEJMoa1501824","journal-title":"N Engl J Med"},{"key":"2837_CR16","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.21037\/tlcr-21-461","volume":"10","author":"A Yoshimura","year":"2021","unstructured":"Yoshimura A, Yamada T, Okuma Y et al (2021) Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study. Transl Lung Cancer Res 10:3582\u20133593. https:\/\/doi.org\/10.21037\/tlcr-21-461","journal-title":"Transl Lung Cancer Res"},{"key":"2837_CR17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s11523-024-01094-5","volume":"19","author":"M Hibino","year":"2024","unstructured":"Hibino M, Imamura Y, Shimoyama R et al (2024) Impact of first-line osimertinib and other EGFR-tyrosine kinase inhibitors on overall survival in untreated advanced EGFR-mutated non-small cell lung cancer in Japan: updated data from TREAD project 01. Target Oncol 19:925\u2013939. https:\/\/doi.org\/10.1007\/s11523-024-01094-5","journal-title":"Target Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02837-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02837-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02837-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T07:38:03Z","timestamp":1758872283000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02837-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2837"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02837-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tadaaki Yamada received grants from Ono Pharmaceutical, Janssen, AstraZeneca, and Takeda Pharmaceutical; personal fees from Eli Lilly; and held a pending patent for PCT\/JP2018\/038202 with Ono Pharmaceutical outside of the submitted work. Hisashi Tanaka received speaking honoraria from Ono Pharmaceutical, Bristol Myers Squibb, AstraZeneca, Chugai Pharmaceutical Co. Ltd, Boehringer Ingelheim, Pfizer, Takeda Pharmaceutical, MSD-Merck, and Amgen. Makoto Hibino received speaking honoraria from Asahi Kasei Pharma Corporation, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai Pharmaceutical Co. Ltd., and Eli Lilly and was involved in a collaborative research project with Shionogi & Co., Ltd. outside the submitted work. Koichi Takayama received research grants from Chugai Pharmaceutical Co. Ltd. and Ono Pharmaceutical and personal fees from AstraZeneca, Chugai Pharmaceutical Co. Ltd., MSD-Merck, Eli Lilly, Boehringer Ingelheim, and Daiichi-Sankyo outside the purview of the submitted work. The remaining authors declared that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict\u00a0 of\u00a0 interest"}},{"value":"All procedures involving human participants in this study were performed in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Ethics Review Board of the Kyoto Prefectural University of Medicine as well as the Ethics Review Board of each hospital (approval no. ERB-C-2988, approval date: November 14, 2023).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"As this was a retrospective study, the need for informed consent was waived by the ethics committee of each hospital. Patients were given the opportunity to opt out on the official study website.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}